Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study
Josephine M Bryant, Dorothy M Grogono, Daniel Greaves, Juliet Foweraker, Iain Roddick, Thomas Inns, Mark Reacher, Charles S Haworth, Martin D Curran, Simon R Harris, Sharon J Peacock, Julian Parkhill, R Andres Floto, Josephine M Bryant, Dorothy M Grogono, Daniel Greaves, Juliet Foweraker, Iain Roddick, Thomas Inns, Mark Reacher, Charles S Haworth, Martin D Curran, Simon R Harris, Sharon J Peacock, Julian Parkhill, R Andres Floto
Abstract
Background: Increasing numbers of individuals with cystic fibrosis are becoming infected with the multidrug-resistant non-tuberculous mycobacterium (NTM) Mycobacterium abscessus, which causes progressive lung damage and is extremely challenging to treat. How this organism is acquired is not currently known, but there is growing concern that person-to-person transmission could occur. We aimed to define the mechanisms of acquisition of M abscessus in individuals with cystic fibrosis.
Method: Whole genome sequencing and antimicrobial susceptibility testing were done on 168 consecutive isolates of M abscessus from 31 patients attending an adult cystic fibrosis centre in the UK between 2007 and 2011. In parallel, we undertook detailed environmental testing for NTM and defined potential opportunities for transmission between patients both in and out of hospital using epidemiological data and social network analysis.
Findings: Phylogenetic analysis revealed two clustered outbreaks of near-identical isolates of the M abscessus subspecies massiliense (from 11 patients), differing by less than ten base pairs. This variation represents less diversity than that seen within isolates from a single individual, strongly indicating between-patient transmission. All patients within these clusters had numerous opportunities for within-hospital transmission from other individuals, while comprehensive environmental sampling, initiated during the outbreak, failed to detect any potential point source of NTM infection. The clusters of M abscessus subspecies massiliense showed evidence of transmission of mutations acquired during infection of an individual to other patients. Thus, isolates with constitutive resistance to amikacin and clarithromycin were isolated from several individuals never previously exposed to long-term macrolides or aminoglycosides, further indicating cross-infection.
Interpretation: Whole genome sequencing has revealed frequent transmission of multidrug resistant NTM between patients with cystic fibrosis despite conventional cross-infection measures. Although the exact transmission route is yet to be established, our epidemiological analysis suggests that it could be indirect.
Funding: The Wellcome Trust, Papworth Hospital, NIHR Cambridge Biomedical Research Centre, UK Health Protection Agency, Medical Research Council, and the UKCRC Translational Infection Research Initiative.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Figures
References
- Chan ED, Bai X, Kartalija M, Orme IM, Ordway DJ. Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease. Am J Respir Cell Mol Biol. 2010;43:387–393.
- Iseman MD, Marras TK. The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2008;178:999–1000.
- Esther CR, Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros. 2010;9:117–123.
- Orens JB, Estenne M, Arcasoy S. International Guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the pulmonary scientific council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745–755.
- Griffith DE, Aksamit T, Brown-Elliott BA. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.
- Jarand J, Levin A, Zhang L. Clinical and microbiologic outcomes in patients receiving treatment for mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52:565–571.
- Adekambi T, Reynaud-Gaubert M, Greub G. Amoebal coculture of “Mycobacterium massiliense” sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol. 2004;42:5493–5501.
- Adekambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bollettii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol. 2006;56(Pt 1):133–143.
- Koh WJ, Jeon K, Lee NY. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183:405–410.
- Stout JE, Floto RA. Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others. Am J Respir Crit Care Med. 2012;186:822–823.
- Lai CC, Tan CK, Chou CH. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008. Emerg Infect Dis. 2010;16:294–296.
- Prevots DR, Shaw PA, Strickland D. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182:970–976.
- Thomson RM, NTM working group at Queensland TB Control Centre and Queensland Mycobacterial Reference Laboratory Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:1576–1583.
- CF Foundation Patient Registry . Annual Data Report to Center Directors 2010. Cystic Fibrosis Foundation; Bethseda, MD: 2011.
- Roux AL, Catherinot E, Ripoll F. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol. 2009;47:4124–4128.
- Renna M, Schaffner C, Brown K. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest. 2011;121:3554–3563.
- Feazel LM, Baumgartner LK, Peterson KL. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci USA. 2009;106:16393–16399.
- Saiman L, Siegel J. Infection Control in Cystic Fibrosis. Clin Microbiol Rev. 2004;17:57–71.
- Olivier KN, Weber DJ, Wallace RJ. Nontuberculous mycobacteria: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:828–834.
- Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis. 2003;9:1587–1591.
- Aitken ML, Limaye A, Pottinger P. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012;185:231–232.
- Harris KA, Kenna DT, Blauwendraat C. Molecular fingerprinting of Mycobacterium abscessus strains in a cohort of pediatric cystic fibrosis patients. J Clin Microbiol. 2012;50:1758–1761.
- Huang WC, Chiou CS, Chen JH, Shen GH. Molecular epidemiology of Mycobacterium abscessus infections in a subtropical chronic ventilator setting. J Med Microbiol. 2010;59:1203–1211.
- Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol. 2007;7:214.
- Ripoll F, Pasek S, Schenowitz C. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PloS One. 2009;4:e5660.
- Macheras E, Roux AL, Bastian S. Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J Clin Microbiol. 2011;49:491–499.
- Leao SC, Tortoli E, Euzeby JP, Garcia MJ. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol. 2011;61(Pt 9):2311–2313.
- Jeon K, Kwon OK, Lee NY. Antibiotic treatment of Myocbacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180:896–902.
- Nash KA, Brown-Elliott BA, Wallace RJ., Jr A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53:1367–1376.
- Kim HY, Kim BJ, Kook Y. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii, by erythromycin ribosome methyltransferase gene (erm) and Clarithromycin susceptibility patterns. Microbiol Immunol. 2010;54:347–353.
- Wallace RJ, Meier A, Brown B. Genetic basis for Clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996;40:1676–1681.
- Falkinham JO., 3rd Nontuberculous Mycobacteria from household plumbing of patient with nontuberculous mycobacteria disease. Emerg Infect Dis. 2011;17:419–424.
- Wiehlmann L, Wagner G, Cramer N. Population structure of Pseudomonas aeruginosa. Proc Nat Acad Sci USA. 2007;104:8101–8106.
- Cystic Fibrosis Trust. Pseudomonas aeruginosa infection in people with cystic fibrosis—suggestions for prevention and infection control, 2nd edn. Report of the UK Cystic Fibrosis Trust Infection Control Group 2004.
- Wallace RJ, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol. 1998;52:453–490.
- Wendt SL, George KL, Parker BC, Gruft H, Falkinham JO., 3rd Epidemiology of infection by nontuberculous mycobacteria. III. Isolation of potentially pathogenic mycobacteria from aerosols. Am Rev Respir Dis. 1980;122:259–263.
Source: PubMed